My research interests are at the interface between nuclear medicine and organic chemistry and focus upon the adaptation of state-of-the-art organic chemistry techniques (including solid-phase organic synthesis and fluorous techniques (www.fluorous.com)) for radiochemical applications, including the simplified synthesis of radiopharmaceuticals.
Such new radiochemistry techniques are then applied to the development of new biomarkers for PET imaging as well as multi-modality (e.g. PET-MRI, PET-CT, PET-optical) applications. The radiochemical techniques at my disposal (and, if appointed, at members of NMIBS disposal through collaborative research projects) also allow for radiolabeling of nanoparticles (e.g. gold nanorods), dendrimers, quantum dots etc. These radiolabeled products can then be used for non-invasive molecular imaging of biochemistry in living human subjects but also, by changing the radioisotope in question, targeted radiotherapy. Use of such biomarkers includes, but is not limited to, neurological (e.g. early diagnosis of Alzheimer’s disease and monitoring of potential AD therapeutic efficacy), oncological (imaging tumors and monitoring chemotherapeutic treatment) and cardiological (e.g. diagnosis of myocardial ischemia) applications.
I embrace the opportunity to get involved in collaborative research with the other members, including contributing to obtaining funding opportunities as appropriate. I would welcome the opportunity to see how radiolabeling could benefit some of MNIMBS current research projects as well as the access to invaluable expertise in other areas that could enhance my own research goals. The radiolabeling of nanoparticles is becoming popular in molecular imaging and offers enticing opportunities to develop novel nanotechnology for medical and life science applications. I would also be happy to mentor any graduate students in the program that have an interest in learning organic synthesis and radiochemistry, and teach classes in these subjects if required.
Dr. Peter Scott received his B.Sc (with first class honors) in medicinal and pharmaceutical chemistry from Loughborough University, UK in 2001 following research into peptide nucleic acids under the guidance of Prof. Raymond Jones. Upon graduating he pursued doctoral research, designing novel multifunctional linker units for solid-phase synthesis (see Eur. J. Org. Chem., 2006, 2251 - 2268), with Dr. Patrick Steel at the University of Durham, UK and was awarded his Ph.D in 2005. Dr. Scott has also edited one book, “Linker Strategies in Solid-phase Organic Synthesis”, due to be published by John Wiley and Sons in 2009. Following his doctoral work, Dr. Scott moved to the United States to pursue postdoctoral research initially in rhodium carbenoid chemistry at the University of Buffalo with Prof. Huw Davies (2005-2006), and subsequently in radiochemistry and PET imaging with Prof. Michael Kilbourn at the University of Michigan (2006-2007). In 2007 he joined Siemens Molecular Imaging and Biomarker Research where he was head of radiochemistry at the LA Tech Center and involved in the design and synthesis of novel radiopharmaceuticals for use in PET imaging. Dr. Scott returned to the University of Michigan School of Medicine in 2009 after being appointed to the faculty of the Department of Radiology. His research interests are at the interface between nuclear medicine and organic chemistry and focus upon the adaptation of state-of-the-art organic chemistry techniques (including SPOS) for radiochemical applications, including the simplified synthesis of novel radiopharmaceuticals and multi-modality (e.g. PET-MRI, PET-CT) molecular probes.